- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02679989
The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)
A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).
Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.
Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.
Objectives:
- A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
- To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
England
-
London, England, Vereinigtes Königreich, SE1 9NH
- Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged >35-75 years
- Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).
REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.
WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.
Exclusion Criteria:
- Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
- previous bariatric surgery or other major surgery (e.g. organ transplantation);
- unable to provide written informed consent;
- have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
- participated in a weight management drug trial in the previous 3 months;
- have binge eating behaviour;
- have uncontrolled epilepsy;
- alcohol or substance abuse;
- currently pregnant, lactating, or planning pregnancy within the study period;
- are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
- lactose intolerant.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Intermittent Energy Restriction
Weight loss intervention: Intermittent Energy Restriction
|
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
|
|
Aktiver Komparator: Continuous Energy Restriction
Weight loss intervention: Continuous Energy Restriction
|
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Revised QUICKI (RQUICKI)
Zeitfenster: Baseline
|
Marker of insulin sensitivity
|
Baseline
|
|
RQUICKI
Zeitfenster: day 29
|
Marker of insulin sensitivity
|
day 29
|
|
RQUICKI
Zeitfenster: day 31
|
Marker of insulin sensitivity
|
day 31
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Körpergewicht
Zeitfenster: Grundlinie
|
Grundlinie
|
|
|
Taillenumfang
Zeitfenster: Grundlinie
|
Grundlinie
|
|
|
Hüftumfang
Zeitfenster: Grundlinie
|
Grundlinie
|
|
|
Plasmaglukosekonzentration
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Plasma-Adiponectin-Konzentration
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Plasma-Leptin-Konzentration
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Gesamtcholesterinkonzentration im Plasma
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Plasma-Cholesterinkonzentration von Low Density Lipoprotein (LDL).
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Plasmakonzentration von High Density Lipoprotein (HDL).
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Plasmatriglyceridkonzentration
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Plasma-Gesamtcholesterin:HDL-Cholesterin-Verhältnis
Zeitfenster: Grundlinie
|
Fasten
|
Grundlinie
|
|
Body-Mass-Index (BMI)
Zeitfenster: Grundlinie
|
Grundlinie
|
|
|
Plasma glucose concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma glucose concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma insulin concentration
Zeitfenster: Baseline
|
Fasting
|
Baseline
|
|
Plasma insulin concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma insulin concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma non-esterified fatty acid concentration
Zeitfenster: Baseline
|
Fasting
|
Baseline
|
|
Plasma non-esterified fatty acid concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma non-esterified fatty acid concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma total cholesterol concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma total cholesterol concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma LDL cholesterol concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma LDL cholesterol concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma HDL cholesterol concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma HDL cholesterol concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma triglyceride concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma triglyceride concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma total cholesterol:HDL cholesterol ratio
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma total cholesterol:HDL cholesterol ratio
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Zeitfenster: Baseline
|
Fasting (calculated from insulin and glucose)
|
Baseline
|
|
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Zeitfenster: day 29
|
Fasting (calculated from insulin and glucose)
|
day 29
|
|
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Zeitfenster: day 31
|
Fasting (calculated from insulin and glucose)
|
day 31
|
|
Plasma adiponectin concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma adiponectin concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma leptin concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma leptin concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma interleukin-6 concentration
Zeitfenster: Baseline
|
Fasting
|
Baseline
|
|
Plasma interleukin-6 concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma interleukin-6 concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma beta-hydroxybutyrate concentration
Zeitfenster: Baseline
|
Fasting
|
Baseline
|
|
Plasma beta-hydroxybutyrate concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma beta-hydroxybutyrate concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma norepinephrine concentration
Zeitfenster: Baseline
|
Fasting
|
Baseline
|
|
Plasma norepinephrine concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma norepinephrine concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Plasma soluble alpha-klotho concentration
Zeitfenster: Baseline
|
Fasting
|
Baseline
|
|
Plasma soluble alpha-klotho concentration
Zeitfenster: day 29
|
Fasting
|
day 29
|
|
Plasma soluble alpha-klotho concentration
Zeitfenster: day 31
|
Fasting
|
day 31
|
|
Body weight
Zeitfenster: day 29
|
day 29
|
|
|
Body weight
Zeitfenster: day 31
|
day 31
|
|
|
BMI
Zeitfenster: day 29
|
day 29
|
|
|
BMI
Zeitfenster: day 31
|
day 31
|
|
|
Waist circumference
Zeitfenster: day 29
|
day 29
|
|
|
Waist circumference
Zeitfenster: day 31
|
day 31
|
|
|
Hip circumference
Zeitfenster: day 29
|
day 29
|
|
|
Hip circumference
Zeitfenster: day 31
|
day 31
|
|
|
Percentage body fat
Zeitfenster: Baseline
|
Baseline
|
|
|
Percentage body fat
Zeitfenster: day 29
|
day 29
|
|
|
Percentage body fat
Zeitfenster: day 31
|
day 31
|
|
|
Percentage lean body mass
Zeitfenster: Baseline
|
Baseline
|
|
|
Percentage lean body mass
Zeitfenster: day 29
|
day 29
|
|
|
Percentage lean body mass
Zeitfenster: day 31
|
day 31
|
|
|
Heart rate variability (resting)
Zeitfenster: Baseline
|
supine
|
Baseline
|
|
Heart rate variability (resting)
Zeitfenster: day 29
|
supine
|
day 29
|
|
Heart rate variability (resting)
Zeitfenster: day 31
|
supine
|
day 31
|
|
Heart rate variability (ambulatory)
Zeitfenster: 24 h recording at baseline
|
24 h recording at baseline
|
|
|
Heart rate variability (ambulatory)
Zeitfenster: 24 h recording on day 29
|
24 h recording on day 29
|
|
|
Heart rate variability (ambulatory)
Zeitfenster: 24 h recording on day 31
|
24 h recording on day 31
|
|
|
Heart rate variability (sleep-time)
Zeitfenster: Baseline
|
Baseline
|
|
|
Heart rate variability (sleep-time)
Zeitfenster: day 29
|
day 29
|
|
|
Heart rate variability (sleep-time)
Zeitfenster: day 31
|
day 31
|
|
|
Heart rate variability (during mental stress)
Zeitfenster: Baseline
|
Baseline
|
|
|
Heart rate variability (during mental stress)
Zeitfenster: day 29
|
day 29
|
|
|
Heart rate variability (during mental stress)
Zeitfenster: day 31
|
day 31
|
|
|
Ambulatory blood pressure 24 h
Zeitfenster: 24 h analysis at baseline
|
24 h analysis at baseline
|
|
|
Ambulatory blood pressure daytime
Zeitfenster: Daytime analysis at baseline
|
Daytime analysis at baseline
|
|
|
Ambulatory blood pressure night-time
Zeitfenster: Night-time analysis at baseline
|
Night-time analysis at baseline
|
|
|
Ambulatory blood pressure 24 h
Zeitfenster: 24 h analysis on day 29
|
24 h analysis on day 29
|
|
|
Ambulatory blood pressure daytime
Zeitfenster: daytime analysis on day 29
|
daytime analysis on day 29
|
|
|
Ambulatory blood pressure night-time
Zeitfenster: night-time analysis on day 29
|
night-time analysis on day 29
|
|
|
Ambulatory blood pressure 24 h
Zeitfenster: 24 h analysis on day 31
|
24 h
|
24 h analysis on day 31
|
|
Ambulatory blood pressure daytime
Zeitfenster: Daytime analysis on day 31
|
day time
|
Daytime analysis on day 31
|
|
Ambulatory blood pressure night-time
Zeitfenster: Night-time analysis on day 31
|
night-time
|
Night-time analysis on day 31
|
|
Digital volume pulse - stiffness index (SI)
Zeitfenster: Baseline
|
Stiffness index
|
Baseline
|
|
Digital volume pulse - SI
Zeitfenster: day 29
|
Stiffness index
|
day 29
|
|
Digital volume pulse - SI
Zeitfenster: day 31
|
Stiffness index
|
day 31
|
|
Digital volume pulse - reflection index (RI)
Zeitfenster: Baseline
|
reflection index
|
Baseline
|
|
Digital volume pulse - RI
Zeitfenster: day 29
|
reflection index
|
day 29
|
|
Digital volume pulse - RI
Zeitfenster: day 31
|
reflection index
|
day 31
|
|
Mnemonic Similarity Test
Zeitfenster: Baseline
|
Baseline
|
|
|
Mnemonic Similarity Test
Zeitfenster: day 29
|
day 29
|
|
|
Mnemonic Similarity Test
Zeitfenster: day 31
|
day 31
|
|
|
Power of food scale
Zeitfenster: Baseline
|
questionnaire
|
Baseline
|
|
Power of food scale
Zeitfenster: day 29
|
questionnaire
|
day 29
|
|
Power of food scale
Zeitfenster: day 31
|
questionnaire
|
day 31
|
|
COPE (not an acronym)
Zeitfenster: Baseline
|
questionnaire
|
Baseline
|
|
COPE
Zeitfenster: day 29
|
questionnaire
|
day 29
|
|
COPE
Zeitfenster: day 31
|
questionnaire
|
day 31
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Adverse events
Zeitfenster: Baseline until endpoint: day 31 (+/-1 day)
|
Baseline until endpoint: day 31 (+/-1 day)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2.
- Harvie M, Wright C, Pegington M, McMullan D, Mitchell E, Martin B, Cutler RG, Evans G, Whiteside S, Maudsley S, Camandola S, Wang R, Carlson OD, Egan JM, Mattson MP, Howell A. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013 Oct;110(8):1534-47. doi: 10.1017/S0007114513000792. Epub 2013 Apr 16.
- Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5.
- Kim C, Pinto AM, Bordoli C, Buckner LP, Kaplan PC, Del Arenal IM, Jeffcock EJ, Hall WL, Thuret S. Energy Restriction Enhances Adult Hippocampal Neurogenesis-Associated Memory after Four Weeks in an Adult Human Population with Central Obesity; a Randomized Controlled Trial. Nutrients. 2020 Feb 28;12(3):638. doi: 10.3390/nu12030638.
- Pinto AM, Bordoli C, Buckner LP, Kim C, Kaplan PC, Del Arenal IM, Jeffcock EJ, Hall WL. Intermittent energy restriction is comparable to continuous energy restriction for cardiometabolic health in adults with central obesity: A randomized controlled trial; the Met-IER study. Clin Nutr. 2020 Jun;39(6):1753-1763. doi: 10.1016/j.clnu.2019.07.014. Epub 2019 Jul 30.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Met-IER2016
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fettleibigkeit, Bauch
-
Albany Medical CollegeAnmeldung auf EinladungFütterungsunverträglichkeit | Abdominal -AusdehnungVereinigte Staaten
-
Carol Davila University of Medicine and PharmacyRekrutierung
-
Azienda Ospedaliero, Universitaria PisanaRekrutierungBiomarker | Infektion, intraabdominal | Sepsis AbdominalItalien
-
Marmara UniversityAbgeschlossenEnterale Ernährung | Magenrestvolumen | Nachrichtentherapie | Abdominal -AusdehnungTruthahn
-
CMH Lahore Medical College and Institute of DentistryRekrutierungNach einer Bauchoperation | Sepsis AbdominalPakistan
-
Kocaeli UniversityAbgeschlossenKoloskopie Schmerzen | Abdominal -AusdehnungTürkei (türkiye)
-
University Health Network, TorontoThe Plastic Surgery Foundation; Canadian Society of Plastic SurgeonsAbgeschlossenTransversus Abdominis Plane (TAP) Blockkatheter | DIEP oder Free MS-TRAM Brustrekonstruktion | Lokale Schmerztherapie | Abdominal-/ SpenderstelleKanada
-
Dongzhimen Hospital, BeijingBeijing University of Chinese MedicineNoch keine RekrutierungGastrointestinale Dysfunktion | Traditionelle Chinesische Medizin | Sepsis AbdominalChina
-
Hangzhou Endonom Medtech Co., Ltd.UnbekanntGuos viszerale Arterienrekonstruktion: Die erste Studie am Menschen zum WeFlow-JAAA-StentgraftsystemJuxta Renal Abdominal Aortenaneurysma ohne RupturChina
-
Akhilesh JainRekrutierungAortenaneurysma | Komplexe Aortenaneurysmen | Juxta Renal Abdominal Aortenaneurysma ohne RupturVereinigte Staaten
Klinische Studien zur Intermittent Energy Restriction
-
George Fox UniversityUnbekanntMuskelschwäche | Kann eine Therapie zur Einschränkung des Blutflusses den Kraftzuwachs in der Rotatorenmanschette steigern?Vereinigte Staaten
-
Gümüşhane UniversıtyAbgeschlossenVeränderung der maximalen Sauerstoffaufnahme (VO₂Max)Türkei (türkiye)
-
Dokuz Eylul UniversityEge UniversityAbgeschlossenMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTruthahn
-
Centre Hospitalier Universitaire de Saint EtienneRekrutierungInfantile spinale Muskelatrophie | Wirbelsäulenamyotrophie | Juvenile spinale MuskelatrophieFrankreich
-
Spaulding Rehabilitation HospitalFoundation Wings For LifeAktiv, nicht rekrutierendVerletzungen des RückenmarksVereinigte Staaten
-
University of FloridaBrooks RehabilitationRekrutierungRückenmarksverletzungen (SCI)Vereinigte Staaten
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology; Vanderbilt University Medical... und andere MitarbeiterAktiv, nicht rekrutierend
-
University of the PacificAbgeschlossenBlutdruck | Elektrischer Wechsel des HerzensVereinigte Staaten
-
Rigshospitalet, DenmarkNoch keine RekrutierungTomographie, Röntgen-Computer | Darm; Ischämisch, chronisch | Dual-Energy-CT
-
Odense University HospitalUnbekannt